Telehealth Helps Breast Cancer Patients Adhere to Treatment: Study

Why It Matters

Higher adherence directly improves survival odds, positioning telehealth as a cost‑effective strategy for oncology care delivery.

Key Takeaways

• Telehealth users 58% more adherent to endocrine therapy
• Study analyzed 1,100+ insured women, five‑year follow‑up
• Reduced transport barriers improve medication persistence
• Virtual visits enable early side‑effect management, boosting adherence
• Results encourage broader telehealth integration in oncology

Pulse Analysis

Telehealth’s rapid expansion during the pandemic has reshaped how chronic cancer treatments are monitored. Endocrine therapy, a cornerstone for hormone‑receptor‑positive breast cancer, demands near‑perfect adherence to reduce recurrence risk. Yet patients often face travel constraints, work conflicts, and side‑effect anxieties that erode compliance. By moving medication check‑ins into virtual platforms, clinicians can maintain frequent contact without the physical burden of clinic visits, preserving the therapeutic momentum essential for long‑term outcomes.

The University of Georgia team leveraged the Merative MarketScan database, a rich source of commercial claims, to track more than 1,100 women from therapy start in 2018 through a five‑year horizon. Their statistical models isolated telehealth encounters as a decisive variable, revealing a 58% uplift in adherence rates. This magnitude rivals many pharmacologic adherence interventions, underscoring how digital access can translate into measurable clinical benefit. Moreover, the study highlights that virtual care mitigates logistical barriers—such as transportation costs and appointment scheduling—while providing a rapid feedback loop for side‑effect management, both of which are known adherence deterrents.

For health systems and payers, the findings make a compelling business case to embed telehealth into oncology pathways. Reimbursement models that support video or phone consultations could lower overall treatment costs by reducing hospitalizations linked to non‑adherence. Policymakers may also consider incentivizing broadband expansion in underserved areas to ensure equitable access. Future research should explore integration with remote monitoring devices and AI‑driven symptom triage to further personalize care. As evidence mounts, telehealth is poised to become a standard adjunct in breast cancer survivorship programs, driving both clinical and economic gains.